Pharmacological inhibition of the Janus Kinases enhances ASCL1 protein stability and transcriptional activity
Molecular Biology Reports · 2025
DOI: 10.1007/s11033-025-10367-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, 2025. Verfasst von Maya A Hanspal und 4 weiteren Autor:innen. Beteiligte Einrichtung: MSD R&D Innovation Centre, 120 Moorgate, London, EC2M 6UR, UK. Hauptthemen laut MEDLINE: Basic Helix-Loop-Helix Proteins, Janus Kinases, Protein Kinase Inhibitors. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Achaete-Scute complex homolog 1 (ASCL1) is a multi-faceted pro-neural transcription factor, playing a role in several processes during embryonic development and into adulthood, including neural progenitor proliferation and neuronal differentiation. This versatility is achieved through tightly controlled expression of ASCL1, either via integrating intracellular signalling cues or stabilisation at the protein level. The role of kinases in ASCL1-mediated neurogenesis is emerging, but to date few kinases have been attributed to act directly or indirectly on ASCL1. METHODS AND RESULTS: To address this, we designed a cell-based high-throughput screen to identify kinase inhibitors that enhance ASCL1 protein levels. From this screen, two kinase inhibitors were identified to increase ASCL1 stability and transcriptional activity, and subsequent validation indicated that the effect was driven indirectly through Janus kinase family members. CONCLUSIONS: These compounds may serve as useful tools for further investigating the role played by kinases in regulating neurogenesis and ultimately enable better understanding of how ASCL1 integrates different signalling cues to orchestrate with high precision the differentiation of progenitor cells into neurons.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MSD R&D Innovation Centre, 120 Moorgate, London, EC2M 6UR, UK.
- Merck & Co., Inc., 320 Bent St., Cambridge, MA, 02141, USA.
- MSD R&D Innovation Centre, 120 Moorgate, London, EC2M 6UR, UK. sebastien.gillotin@msd.com.
Zitieren
APA
Hanspal, M. A., Presland, J., Shkura, K., Veiga, M. K., & Gillotin, S. (2025). Pharmacological inhibition of the Janus Kinases enhances ASCL1 protein stability and transcriptional activity. Molecular Biology Reports. https://doi.org/10.1007/s11033-025-10367-9
Vancouver
Hanspal MA, Presland J, Shkura K, Veiga MK, Gillotin S. Pharmacological inhibition of the Janus Kinases enhances ASCL1 protein stability and transcriptional activity. Molecular Biology Reports. 2025. doi:10.1007/s11033-025-10367-9
BibTeX
@article{Hanspal2025,
author = {Hanspal, Maya A and Presland, Jeremy and Shkura, Kirill and Veiga, Martina Koeva and Gillotin, Sébastien},
title = {Pharmacological inhibition of the Janus Kinases enhances ASCL1 protein stability and transcriptional activity},
journal = {Molecular Biology Reports},
year = {2025},
doi = {10.1007/s11033-025-10367-9}
}
EUVIMED